Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.80 +0.01 (+0.09%)
At close: Sep 9, 2026 · 4:00 PM EDT

Drugs Made In America Acquisition (DMAA) Assets Average (2025 - 2026)

Drugs Made In America Acquisition's (DMAA) quarterly Assets Average came in at $193.4 million in Q2 2026, down 17.35% on a YoY basis from $234.0 million in Q2 2025, and down 19.0% quarter-over-quarter from $238.8 million in Q4 2025.

Analysis

Drugs Made In America Acquisition (DMAA) Assets Average (2025 - 2026) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has reported Assets Average for 2 consecutive years, with $193.4 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Assets Average fell 17.35% year-over-year to $193.4 million; the trailing twelve-month figure through Jun 2026 stood at $193.4 million (down 17.35% YoY), and the FY2025 full-year result was $120.2 million, changed N/A from the prior year.
  • Assets Average retreated to $193.4 million in Q2 2026 per DMAA's latest filing, from $238.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $238.8 million in Q4 2025 and bottomed at $116.7 million in Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Assets Avg. (Qtr)
1 Blackstone 102.43 Bn 104.87 Bn - 49.11 Bn
2 Kkr 96.71 Bn -180.36 Bn - -
3 Brookfield Asset Management 80.84 Bn 80.57 Bn - 19.01 Bn
4 Apollo Global Management 76.99 Bn 72.09 Bn 10.54 Bn 480.79 Bn
5 Wheaton Precious Metals 70.37 Bn 70.27 Bn 687.86 Mn 11.00 Bn
6 Franco Nevada 51.31 Bn 49.77 Bn 451.00 Mn 8.86 Bn
7 Ares Management 50.50 Bn 55.42 Bn - 29.01 Bn
8 Brookfield 37.98 Bn 7.42 Bn 19.38 Bn 301.93 Bn
9 Tpg 20.58 Bn 22.14 Bn - 13.67 Bn
10 Drugs Made In America Acquisition 332.47 Mn 332.47 Mn - 193.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 193.41 Mn
Dec 31, 2025 238.78 Mn
Sep 30, 2025 236.42 Mn
Jun 30, 2025 234.01 Mn
Mar 31, 2025 116.68 Mn